

# POSTERS EUROGIN 2019

## P 02 Epidemiology and natural history

<b>P 02-1</b>	Retrospective analysis of the tracking of the uterine cervix cancer on women under 25 years old, during 5 years, made in Valença city, state of Rio de Janeiro Brazil	<b>Silveira F.</b>	<b>Brazil</b>
<b>P 02-2</b>	Preliminary analysis on the genetic diversities of high-risk human papillomaviruses in Chinese women	<b>Ou Z.</b>	<b>China</b>
<b>P 02-3</b>	Prevalence of abnormal Pap smear and detection of intraepithelial cervical lesions in a population of women who participated in a campaign for cervical cancer prevention at Buenos Aires´ University Hospital	<b>Fleider L. A.</b>	<b>Argentina</b>
<b>P 02-4</b>	The clinical significance and utility of HPV-DNA testing in Korean women with atypical glandular cells in cervical Pap tests: An analysis of 311 cases at a single institution	<b>Jang T-K.</b>	<b>South Korea</b>
<b>P 02-5</b>	Head and neck cancer and cervical cancer detection in Russia	<b>Briko N.</b>	<b>Russia</b>

## P 04 Immunology

<b>P 04-1</b>	Epithelial stromal cross talk in HPV/HIV infection	<b>Sibeko S.</b>	<b>South Africa</b>
<b>P 04-2</b>	The concentrations of FAS/APO-1 antigen in HeLa cell lines incubated with retinol	<b>Darmochwal-Kolarz D.</b>	<b>Poland</b>

## P 05 HPV prophylactic vaccines

<b>P 05-1</b>	Long-term immunogenicity and effectiveness of the 9-valent HPV (9vHPV) vaccine in preadolescents and adolescents	<b>Olsson S. E.</b>	<b>Sweden</b>
<b>P 05-2</b>	Understanding confidence in human papillomavirus vaccine in Japan: a web-based questionnaire survey of mothers, female adolescents, and health care professionals	<b>Shuto M.</b>	<b>Japan</b>
<b>P 05-3</b>	Continuing evolution of gender-neutral HPV vaccination: an update on national immunization programs and evidence gaps associated with GNV policy development and program implementation	<b>Morais E.</b>	<b>France</b>
<b>P 05-4</b>	Immunogenicity and safety of a 9-valent human papillomavirus vaccine in Vietnamese males and females (9-26 years of age): an open-label, phase 3 trial	<b>Group T.</b>	<b>USA</b>
<b>P 05-5</b>	HPV vaccine acceptance among women aged 25 to 45 in Slovenia: results of the coheahr study	<b>Šterbenc A.</b>	<b>Slovenia</b>
<b>P 05-6</b>	Reasons for participation in a HPV vaccine dose reduction clinical trial in sub-Saharan Africa: Does dose matter?	<b>Watson-Jones D.</b>	<b>Tanzania</b>
<b>P 05-7</b>	Changes the past decade after the introduction of the human papillomavirus (HPV) vaccine in cervical HPV prevalence at a youth clinic in Stockholm, Sweden	<b>Dalianis T.</b>	<b>Sweden</b>

<b>P 08</b>	<b>HPV testing</b>		
<b>P 08-1</b>	Risk factors for type-specific persistence of human papillomavirus and recurrence of cervical intraepithelial neoplasia after conization	<b>Min K. J.</b>	<b>South Korea</b>
<b>P 08-2</b>	Comparison of two commercial HPV testing assays for detection of high-risk HPV in head and neck fine-needle aspiration biopsy specimens	<b>Guo M.</b>	<b>USA</b>
<b>P 08-3</b>	Do multiple versus single HPV infections have a greater oncogenic potential in the etiopathogenesis of cervical intraepithelial lesions II+?	<b>Zivadinovic R.</b>	<b>Serbia</b>
<b>P 08-4</b>	Prevalence of HPV types among women in Vojvodina - Distribution of HPV among healthy population	<b>Milosevic V.</b>	<b>Serbia</b>
<b>P 08-5</b>	Study of HPV infectivity of women with cervical pathologies	<b>Zakhirova N.</b>	<b>Uzbekistan</b>
<b>P 08-6</b>	Multi-Site Comparative Study of the BD COR™ System and the BD Viper™ LT System Using the BD Onclarity™ HPV Assay	<b>Greene W.</b>	<b>USA</b>
<b>P 08-7</b>	Papilloplex: Development of a stand-alone solution for the screening of High Risk, Low Risk HPV as well as detection of mRNA expression for triage in cervical cancer screening.	<b>Fu G.</b>	<b>UK</b>
<b>P 08-8</b>	Multi-site evaluation of the BD COR™ System using the BD Onclarity™ HPV assay with specimens collected in BD Surepath™ media and preservcyt solution	<b>Von Bredow B.</b>	<b>USA</b>
<b>P 08-9</b>	Low-cost POC for the detection and genotyping of high-risk HPV suitable for low resourced settings	<b>Murton H.</b>	<b>UK</b>
<b>P 09</b>	<b>HPV screening</b>		
<b>P 09-1</b>	Basic study of whether detection of HPV-DNA in the first-void urine is useful as a marker of cervical HPV infection	<b>Wada T.</b>	<b>Japan</b>
<b>P 09-3</b>	Can colposcopy be delayed for HPV positive women with normal to low risk cytology?	<b>McGauran M.</b>	<b>Australia</b>
<b>P 09-4</b>	Accuracy of mRNA HPV and DNA hrHPV tests compared in pairs for cervical cancer screening: a systematic review and meta-analysis	<b>Macedo A. C.</b>	<b>Brazil</b>
<b>P 09-5</b>	HPV and cervical cancer - screening and vaccination strategies in Romania	<b>Mitran M.</b>	<b>Romania</b>
<b>P 09-6</b>	HPVpro study: comparison of HPV detection in cervical and cervicovaginal swabs	<b>Koudelakova V.</b>	<b>Czech Republic</b>
<b>P 09-7</b>	Differences in risk between vaccinated and unvaccinated women against human papillomavirus and herd immunity: towards a personalized screening approach	<b>Naslazi E.</b>	<b>Netherlands</b>
<b>P 09-8</b>	Application of the self-sampling diagnostic test for evaluation of human papillomavirus in women	<b>Apolikhina I.</b>	<b>Russia</b>

**P 10 Self-sampling**

<b>P 10-1</b>	A cervical cancer screening theory of change using Fuzzy Cognitive Mapping with Inuit women in Nunavik, Northern Quebec, Canada	<b>Brassard P.</b>	<b>Canada</b>
<b>P 10-2</b>	Self-sampling for HPV testing in elderly women	<b>Hermansson R.</b>	<b>Sweden</b>
<b>P 10-3</b>	Performance evaluation of INNO-LIPA® HPV genotyping extra II on first-void urine	<b>Riems N.</b>	<b>Belgium</b>
<b>P 10-4</b>	Evaluation of HPV testing with Papillocheck® on Floqswabs® self-collected samples	<b>Gruenbart D.</b>	<b>Austria</b>
<b>P 10-5</b>	Women attending routine screening who test hrHPV negative on a self sample are at very low risk of disease over 5 years; lessons from the PaVdaG cohort	<b>Stanczuk G.</b>	<b>UK</b>
<b>P 10-6</b>	Standardized and volumetric collection of first-void urine for detection of STIs and HPV: A comparison between Colli-Pee® and a standard urine cup	<b>Meers N.</b>	<b>Belgium</b>
<b>P 10-7</b>	Acceptability and accuracy of cervical cancer screening using a self-collected veil for HPV DNA testing by multiplex real-time PCR among adult women in sub-Saharan Africa	<b>Mboumba Bouassa R-S.</b>	<b>France</b>

**P 11 Genotyping**

<b>P 11-1</b>	Evaluation of p16/Ki-67 Dual Staining Compared with HPV Genotyping in Anal Cytology with Diagnosis of ASC-US for Detection of High-Grade Anal Intraepithelial Lesions	<b>Mekki Y.</b>	<b>France</b>
<b>P 11-2</b>	Genotyping of human papillomavirus (HPV) in a healthy patient population and in patients with suspected cervical intraepithelial neoplasia	<b>Pruski D.</b>	<b>Poland</b>
<b>P 11-3</b>	Prevalence of sexually transmitted infections among women living in remote areas along the Amazon rivers - Brazil	<b>Zonta M. A.</b>	<b>Brazil</b>
<b>P 11-4</b>	Evolutionary prevalence of different human papillomavirus genotypes from uterine cervix smears in France: a regional experience of a laboratory using the clart® HPV test (Genomica - Madrid - Spain) between 2014 and 2018	<b>Giovannelli G.</b>	<b>France</b>

**P 12 Molecular markers**

<b>P 12-1</b>	Performance of p16/ki67 immunostaining as a screening tool for colposcopy in women presenting with low grade intraepithelial lesion at cervical cytology	<b>Galvão A.</b>	<b>Portugal</b>
<b>P 12-2</b>	Prognostic value of FISH hybridization technique in cervical cancer patients	<b>Kudela E.</b>	<b>Slovakia</b>
<b>P 12-4</b>	Episomal HPV16 and aggressive metastatic anal squamous cell carcinoma: molecular description by HPV Capture technology coupled with next generation sequencing; a case report	<b>Wack M.</b>	<b>France</b>
<b>P 12-4</b>	Immunohistochemistry markers in the diagnosis of H-SIL	<b>Dimitriadi T.</b>	<b>Russia</b>

**P 13 Screening for women difficult to reach**

<b>P 13-1</b>	Implementation of primary and secondary cervical cancer prevention in the Regional center of cervical pathology	<b>Dimitriadi T.</b>	<b>Russia</b>
<b>P 13-2</b>	Prevalence of CIN2+ among ASCUS smears in Isère department	<b>Garnier A.</b>	<b>France</b>
<b>P 13-3</b>	Organized vs. opportunistic Screening: a Portuguese oncology centre experience	<b>Martins L.</b>	<b>Portugal</b>
<b>P 13-4</b>	HPV prevalence and HPV-related dysplasia in elderly women	<b>BergLindström A.</b>	<b>Sweden</b>

**P 17 Methylation**

<b>P 17-1</b>	DNA methylation analysis in HPV-positive screening samples from women 30-69 years in the cervical cancer-screening program in Örebro, Sweden - a pilot study	<b>Kaliff M.</b>	<b>Sweden</b>
<b>P 17-2</b>	The methylated PAX1 gene used as follow up biomarker for cervical intraepithelial neoplasia and cervical cancer treatment	<b>Xie R.</b>	<b>China</b>

**P 18 Microbiome**

<b>P 18-1</b>	Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study	<b>Wiik J.</b>	<b>Sweden</b>
<b>P 18-2</b>	Relationship between vaginal microbiota and HPV infection	<b>Tatti S. A.</b>	<b>Argentina</b>

**P 20 New technologies**

<b>P 20-1</b>	The causes for dual p16/ki-67 evaluation false results on conventional smears	<b>Kloboves Prevodni V.</b>	<b>Slovenia</b>
<b>P 20-2</b>	An infectious pseudovirion of HPV with thymidine kinase as a tool of gene therapy	<b>Ito R.</b>	<b>Japan</b>

**P 22 Diagnostic procedures / management**

<b>P 22-1</b>	Towards identification of HPV diagnostic and prognostic biomarkers using machine learning on HPV integration clinical data obtained by molecular combing	<b>Mahé F.</b>	<b>France</b>
<b>P 22-2</b>	Adenosarcoma in cervical polyp	<b>Przybylski M.</b>	<b>Poland</b>

**P 23 Colposcopy**

<b>P 23-1</b>	Does dynamic spectral imaging colposcopy improve the diagnostic accuracy of cervical dysplasia?	<b>Booth B. B.</b>	<b>Denmark</b>
<b>P 23-2</b>	Effects of orally administered preliminary analgesic therapy in diagnostic colposcopy patients: a prospective questionnaire study	<b>Michail G.</b>	<b>Greece</b>

**P 24 Cervical neoplasia**

<b>P 24-1</b>	Management of cervical intraepithelial neoplasia 2 in young women	<b>Suh D. H.</b>	<b>South Korea</b>
<b>P 24-2</b>	Case report of an alternative treatment for recurrent cervical and vaginal dysplasia in patient with persistent HPV infection	<b>Šavrora A.</b>	<b>Estonia</b>
<b>P 24-3</b>	Association of a genetic variant in ATP-binding cassette sub-family B member 1 with risk of developing cervical cancer	<b>Hasanzadeh Mofrad M.</b>	<b>Afghanistan</b>
<b>P 24-4</b>	Our experiences with diagnosis and results of cervical pathology treatment	<b>Dörr A.</b>	<b>Czech Republic</b>
<b>P 24-5</b>	Diagnostic performance of p16/ki67 immunostaining in comparison with HPV DNA and mRNA assays to identify high grade cervical intraepithelial neoplasia in women with minor abnormal cytology. The Greek experience	<b>Nasioutzki M.</b>	<b>Greece</b>
<b>P 24-6</b>	New risk factors affecting cervical cancer stage IB in revised FIGO staging	<b>Jung Y.</b>	<b>South Korea</b>
<b>P 24-7</b>	Clear cell carcinoma of cervix: a case series from a single center	<b>Kim Y-T.</b>	<b>South Korea</b>
<b>P 24-8</b>	Trend analysis of cytological abnormalities in opportunistic cervical screening among young women in the Netherlands	<b>Schurink-VanT Klooster T.</b>	<b>Netherlands</b>
<b>P 24-9</b>	Efficacy of collagen sealant for reducing hemorrhage after loop electrocauterial excisional procedure (LEEP)	<b>Kim W. Y.</b>	<b>South Korea</b>
<b>P 24-10</b>	HPV16-associated adenocarcinoma	<b>Pacheco A.</b>	<b>Portugal</b>
<b>P 24-11</b>	Effect of a coriolous versicolor-based vaginal gel in high-risk HPV infected patients. Results of different studies.	<b>Seydoux G.</b>	<b>Spain</b>

**P 26 Vulvar diseases and neoplasia**

<b>P 26-1</b>	Clinical feature and HPV prevalence in vulvar intraepithelial neoplasia	<b>Jeon S.</b>	<b>South Korea</b>
<b>P 26-2</b>	Prevalence of HPV and p16 expression in vulvar squamous cell carcinoma: a population-based danish study of >1,500 cancers	<b>Thomsen L. T.</b>	<b>Denmark</b>

**P 28 Oral HPV infection**

<b>P 28-1</b>	Natural history of oral human papillomavirus infection in healthy populations: design of the prevalence of oral HPV infection, a global assessment, the progress study	<b>Morais E.</b>	<b>France</b>
---------------	--	------------------	---------------

<b>P 29</b>	<b>HPV and oropharynx / Head and neck cancer</b>		
<b>P 29-1</b>	Genomic characterization of clonal evolution during oropharyngeal carcinogenesis driven by HPV 16	<b>Kim J-H.</b>	<b>South Korea</b>
<b>P 29-2</b>	A retrospective study of intra-arterial chemotherapy with concurrent radiotherapy for resectable locally advanced HPV-positive oropharyngeal carcinoma	<b>Aga M.</b>	<b>Japan</b>
<b>P 29-3</b>	The influence of human papillomavirus on nasopharyngeal carcinoma in Japan	<b>Yoshizaki T.</b>	<b>Japan</b>
<b>P 29-4</b>	Changes in incidence and prevalence of human papillomavirus in tonsillar and base of tongue cancer during 2000-2016 in the Stockholm region and Sweden	<b>Holzhauser S.</b>	<b>Sweden</b>
<b>P 29-5</b>	Ectopic chromosome around centrosome (ECAC) as a potential marker of human papillomavirus (HPV) infection on oropharyngeal carcinoma	<b>Kobayashi E.</b>	<b>Japan</b>
<b>P 29-6</b>	Predictive value of 18F-FDG metabolic tumor volume and total lesion glycolysis for systemic metastasis in tonsil cancer	<b>Kim S-Y.</b>	<b>South Korea</b>
<b>P 29-7</b>	Attributable fraction of HPV related head and neck cancers in the recurrent / metastatic setting. A literature review of PHI-III clinical trials	<b>Athanasopoulos C.</b>	<b>Greece</b>
<b>P 29-8</b>	Familial association of oropharyngeal and anogenital HPV-cancers is calendar-time dependent	<b>Lehtinen M.</b>	<b>Germany</b>
<b>P 29-10</b>	DRH1 - Evaluating a blood-based marker for HPV16-induced tumors	<b>Weiland T.</b>	<b>Austria</b>
<b>P 30</b>	<b>HPV and associated skin diseases</b>		
<b>P 30-1</b>	Determination of caUSAtive human papillomavirus type in histologically confirmed common warts, based on estimated viral loads	<b>Fujs Komloš K.</b>	<b>Slovenia</b>
<b>P 31</b>	<b>Genital warts</b>		
<b>P 31-1</b>	Characteristics of human papillomavirus 6 and 11 infection in anogenital warts and corresponding hair follicles over the period of two years	<b>Hošnjak L.</b>	<b>Slovenia</b>

**P 35 Advocacy, acceptability and psychology**

<b>P 35-1</b>	Safety first: elderly women's experiences with HPV testing, cytology and colposcopy, and views on preventive treatment for cervical cancer	<b>Gustafson L. W.</b>	<b>Denmark</b>
<b>P 35-2</b>	Increasing screening uptake: training Japanese nurses to perform cervical screening	<b>Kudo R.</b>	<b>Japan</b>

**P 38 Public health**

<b>P 38-1</b>	Evolution of the HPV vaccine coverage in France: a French claims data study	<b>Dominiak G.</b>	<b>France</b>
<b>P 38-2</b>	Knowledge and attitudes to hpv vaccine in a group of women who participated on a cervical cancer prevention campaign	<b>Tatti S. A.</b>	<b>Argentina</b>
<b>P 38-3</b>	Modeling for predictors of knowledge score on aetiology and prevention strategies for cervical cancer among women of reproductive age in Ibadan	<b>Morhason-Bello I.</b>	<b>Nigeria</b>
<b>P 38-4</b>	Japan and UK collaboration to support HPV based interventions for the prevention of cervical cancer	<b>Hanley S.</b>	<b>Japan</b>
<b>P 38-5</b>	Topical therapeutic drugs are essential to reducing the extreme global disparities in human papillomavirus diseases and deaths	<b>Broker T.</b>	<b>USA</b>
<b>P 38-6</b>	Human papillomavirus (HPV) prevalence and genotypes distribution in the general female population of southern Croatia (Dalmatia county)	<b>Kaliterna V.</b>	<b>Croatia</b>

**P 39 Fertility and HPV**

<b>P 39-1</b>	Human papillomavirus infection in men from couples treated for infertility and its Impact on fertility outcome	<b>Jaworek H.</b>	<b>Czech Republic</b>
---------------	--	-------------------	-----------------------